Aptima® CMV Quant Assay

FDA-Approved solution to reliably and efficiently deliver actionable viral load insights to post-transplant patients and their care teams.

CMV and Viral Load Monitoring

Cytomegalovirus (CMV) infection is a common complication that affects organ transplant patients. CMV, a member of the herpes virus family, establishes a lifelong latent infection that is generally asymptomatic. However, in immunocompromised patients, such as transplant recipients, reactivation of latent CMV is often life-threatening. Guidelines recommend regular monitoring of CMV viral load as an aid for diagnosis of CMV infections and monitoring response to treatment.

The Aptima CMV Quant assay intended use is to:

Monitor Viral Load
Assess viral response to treatment with
serial DNA measurements in patients receiving
anti-CMV therapy.

Inform Care
Aid in the management of solid-organ transplant patients and hematopoietic stem cell transplant patients.